Search results
Results from the WOW.Com Content Network
Romosozumab, sold under the brand name Evenity (/ ɪ ˈ v ɛ n ɪ t i / ih-VENN-ih-tee or with the pin-pen merger, / ɪ ˈ v ɪ n ɪ t i / ih-VINN-ih-tee), is a medication used to treat osteoporosis. [7] [8] It has been found to decrease the risk of fractures of the spine. [7] Common side effects include headache, joint pain, and injection site ...
Amgen (AMGN) gets approval in the United States for osteoporosis drug, Evenity. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290 ...
GoodRx released a list of 19 of the most influential drugs and vaccines approved by the FDA in 2024 to treat a variety of conditions. These medications are “slated to make a big clinical impact."
2010: On June 6, 2010, Amgen received FDA approval for Prolia, a protein drug for the treatment of post-menopausal osteoporosis. [45] In clinical trials, Prolia reduced the rate of vertebral fractures by 61% and the risk of hip fractures by 40%. [ 46 ]
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
The EC grants marketing authorization to Amgen (AMGN) and partner UCB's Evenity for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.
The CHMP provides an unfavorable feedback to Amgen's (AMGN) marketing application for Evenity to treat severe osteoporosis in postmenopausal women with risk of fracture.
Approved by FDA in May 2018. [13] In February 2019, the European CHMP of EMA recommended the granting of a conditional marketing authorisation for Andexanet alfa (in EU: Ondexxya ). [ 14 ] In April 2019 the European Commission granted the authorisation (approved) Andexanet for the 28 countries of the EU.